Progress in the SERENITY At-Home Phase 3 Trial
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a pioneering biopharmaceutical company, has recently announced a key development in its clinical research. This pertains to the completion of the last patient visit in their Phase 3 SERENITY At-Home trial. This clinical trial aims to evaluate the safety and effectiveness of BXCL501, an innovative treatment option for patients experiencing agitation associated with bipolar disorders and schizophrenia.
A Milestone in Agitation Treatment
The SERENITY At-Home Phase 3 trial represents a significant step forward for BioXcel Therapeutics. As the trial wraps up, it has successfully enrolled over 200 patients across 22 sites, all of whom have participated in this double-blind, placebo-controlled study. Patients received a dose of 120 mcg of BXCL501 during periods of agitation, and their safety and response were carefully monitored throughout the 12-week trial period.
Understanding the Need for Home-Based Care
An estimated 23 million episodes of agitation related to bipolar disorder and schizophrenia occur annually in home settings across the United States. Despite this high prevalence, there are currently no FDA-approved treatments for this condition when experienced outside of hospital environments. BioXcel’s efforts aim to fill this critical gap with BXCL501, which could offer much-needed relief for patients facing these challenges.
Insights from the CEO
“This marks a major milestone in our efforts to bring a much-needed at-home (outpatient) treatment option to the millions of individuals who experience agitation related to bipolar disorders or schizophrenia,” stated Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. His commitment to this cause is evident, expressing gratitude to patients, caregivers, and clinical teams who made the continuity of this trial possible.
The SERENITY Trial Design
The design of the SERENITY At-Home trial is crucial in gauging the drug's effectiveness. Patients administered BXCL501 themselves, with the study structured to assess their experience and any side effects through various methods, including the modified Clinical Global Impression scale. This careful approach allows for a comprehensive view of the treatment's impact and its potential for future use in outpatient settings.
About BXCL501
BXCL501, developed by BioXcel Therapeutics, is a sublingual film formulation of dexmedetomidine, a drug originally approved for different medical uses. The focus on its application for outpatient settings adds a layer of innovation to its value proposition. This drug is currently also under investigation for treating agitation in conditions such as Alzheimer’s dementia and has received Breakthrough Therapy designation for its potential uses.
More About IGALMI
IGALMI (dexmedetomidine) is a prescription medication intended for rapid relief of agitation in adults. While it has shown promise for the acute treatment of agitation in specific patient populations, it is important for patients to remain under healthcare supervision while using this medication to monitor vital signs and avoid adverse effects. The safety profile is critical, especially since common side effects include sleepiness, dizziness, and drops in blood pressure.
Important Safety Information
Patients should be aware that IGALMI can lead to serious side effects, including decreased blood pressure and profound drowsiness. Users must refrain from activities that require mental alertness right after administration. Additionally, the medication should be administered under a healthcare provider’s supervision, ensuring appropriate monitoring and guidance.
Conclusion and Future Outlook
With the last patient visit completed, BioXcel Therapeutics prepares for the awaited topline data readout from the SERENITY At-Home trial. This data could potentially pave the way for the submission of a supplemental New Drug Application (sNDA) as part of the company’s strategy for advancing BXCL501 for broader use in home settings for patients suffering from agitation related to bipolar disorders and schizophrenia.
Frequently Asked Questions
1. What is the SERENITY At-Home trial?
The SERENITY At-Home trial is a Phase 3 clinical trial evaluating the safety and effectiveness of BXCL501 for the acute treatment of agitation in bipolar disorders and schizophrenia patients at home.
2. How many patients were involved in the trial?
Over 200 patients participated in the SERENITY At-Home trial across 22 different sites.
3. What is BXCL501?
BXCL501 is an investigational drug formulated as a sublingual film designed to treat agitation, primarily related to bipolar disorders and schizophrenia.
4. What is IGALMI?
IGALMI (dexmedetomidine) is a prescription medication used for the acute treatment of agitation, requiring administration under the supervision of healthcare professionals.
5. What are the common side effects of using IGALMI?
The most common side effects include drowsiness, dizziness, and drops in blood pressure. Patients should consult with their healthcare provider regarding any concerns.
